Completed
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
NCT06312020· Phase 2· Horizon Therapeutics Ireland Designated Activity Company· Source
Completed
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis
2024-512417-41-00· Phase 3· Xentria Inc.· Source
Completed
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
NCT06920771· Phase 3· HAL Allergy· Source
Completed
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
NCT06588738· Phase 3· Alumis Inc· Source
Completed
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003· Phase 3· Arrowhead Pharmaceuticals· Source
Completed
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403· Phase 3· Ipsen· Source
Completed
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
NCT06551064· Phase 1· Formycon AG· Source
Completed
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
NCT06347133· Phase 3· Arrowhead Pharmaceuticals· Source
Completed
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124· Phase 3· Amgen· Source
Completed
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis
2023-503790-37-00· Phase 3· Curateq Biologics Private Limited· Source
Completed
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis
2022-503005-38-00· Phase 2· Landos Biopharma Inc.· Source
Completed
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.
2022-502778-18-00· Phase 3· Polpharma Biologics S.A.· Source
Completed
Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS)
2023-503915-14-00· Phase 2· Argenx· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period
NCT06108544· Phase 3· Takeda· Source
Completed
The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the trial around the participant, known as decentralised, and hybrid clinical trials compared to standard clinical trials that take place in hospitals or in research centres, in patients with type 2 diabetes mellitus treated with Toujeo®, a drug to help manage blood sugar levels.
2022-500449-26-00· Phase 4· University Medical Center Utrecht· Source
Completed
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
NCT05852431· Phase 3· 89bio, Inc.· Source
Completed
Comparative efficacy, safety, pharmacokinetic, and immunogenicity study of LY06006 and EU-Prolia in postmenopausal women with osteoporosis
NCT05853354· Phase 3· Shandong Boan Biotechnology Co. Ltd.· Source
Completed
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s disease
NCT05543252· Phase 2· UCB Biopharma· Source
Completed
A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus
NCT05306574· Phase 3· Remegen Co. Ltd.· Source
Completed
A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
NCT05610280· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Completed
An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)
NCT05477524· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609· Phase 1/2· Ascendis Pharma Oncology Division A/S· Source
Completed
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
NCT05013905· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source
Completed
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
NCT04996797· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source
Terminated
Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis
NCT04864392· Phase 2· Novartis Pharmaceuticals· Source
Completed
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435· Phase 3· Bristol-Myers Squibb· Source
Completed
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· Phase 3· Amgen· Source
Completed
Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease
2024-511553-22-00· Phase 3· Celgene International II SARL· Source